COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance.
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
23 Nov 2023
23 Nov 2023
Historique:
medline:
27
11
2023
pubmed:
23
11
2023
entrez:
23
11
2023
Statut:
ppublish
Résumé
The COVID-19 pandemic saw unprecedented resources and funds driven into research for the development, and subsequent rapid distribution, of vaccines, diagnostics and directly acting antivirals (DAAs). DAAs have undeniably prevented progression and life-threatening conditions in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, there are concerns of antimicrobial resistance (AMR), antiviral resistance specifically, for DAAs. To preserve activity of DAAs for COVID-19 therapy, as well as detect possible mutations conferring resistance, antimicrobial stewardship and surveillance were rapidly implemented in England. This paper expands on the ubiquitous ongoing public health activities carried out in England, including epidemiologic, virologic and genomic surveillance, to support the stewardship of DAAs and assess the deployment, safety, effectiveness and resistance potential of these novel and repurposed therapeutics.
Identifiants
pubmed: 37995354
pii: 7444805
doi: 10.1093/jac/dkad314
pmc: PMC10666993
doi:
Substances chimiques
Anti-Bacterial Agents
0
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
ii37-ii42Subventions
Organisme : UKRI MRC
ID : MR/N00065X/1
Organisme : National Institute for Health Research
Organisme : Health Protection Research Unit
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Références
Lancet Infect Dis. 2022 Nov;22(11):e311-e326
pubmed: 35803289
JAC Antimicrob Resist. 2022 Mar 18;4(2):dlac016
pubmed: 35310572
Antibiotics (Basel). 2021 Jan 23;10(2):
pubmed: 33498716
Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1934-8
pubmed: 1371886
Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):11613-11618
pubmed: 30352857
BMJ Open. 2022 Mar 2;12(3):e048502
pubmed: 35236729
Int J Infect Dis. 2021 Dec;113:103-108
pubmed: 34624517
Nat Protoc. 2021 Jun;16(6):3114-3140
pubmed: 33893470
J Am Coll Clin Pharm. 2022 Jul;5(7):707-715
pubmed: 35572210
J Clin Lab Anal. 2022 Jan;36(1):e24151
pubmed: 34851526
BMJ. 2022 Jan 11;376:o61
pubmed: 35017202
N Engl J Med. 2022 Apr 14;386(15):1475-1477
pubmed: 35263535
Curr Infect Dis Rep. 2020;22(9):23
pubmed: 32834785
Nat Med. 1996 Jul;2(7):760-6
pubmed: 8673921
Am J Health Syst Pharm. 2021 Mar 31;78(8):743-750
pubmed: 33543233
N Engl J Med. 2022 Apr 14;386(15):1477-1479
pubmed: 35263515
J Am Coll Clin Pharm. 2020 Dec;3(8):1480-1492
pubmed: 33043280
Infection. 2023 Feb;51(1):21-35
pubmed: 35438413
BMJ Med. 2023 Jan 13;2(1):e000276
pubmed: 36936265
Ann Med. 2022 Dec;54(1):516-523
pubmed: 35118917
N Engl J Med. 2022 Jun 23;386(25):2436-2438
pubmed: 35675197
Antimicrob Resist Infect Control. 2021 Sep 28;10(1):138
pubmed: 34583775
AIDS. 1995 Dec;9 Suppl 2:27-S32
pubmed: 8775804
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468
pubmed: 32358954
PLoS One. 2021 May 6;16(5):e0251170
pubmed: 33956882
J Infect Dis. 1992 Jan;165(1):105-10
pubmed: 1370174
Science. 1989 Dec 1;246(4934):1155-8
pubmed: 2479983
Mayo Clin Proc. 2020 Sep;95(9S):S29-S32
pubmed: 32948257